Clinical Trials Logo

Immunocompromised Patients clinical trials

View clinical trials related to Immunocompromised Patients.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04680884 Not yet recruiting - Clinical trials for Acute Respiratory Failure

Empirical Steroids and/or Antifungals in Immunocompromised Patients With Acute Respiratory Failure From Undetermined Etiology: a Multicenter Double-blind Randomized Controlled Trial

EFRAIM II
Start date: December 21, 2020
Phase: Phase 3
Study type: Interventional

Acute respiratory failure (ARF) is the leading reason of ICU admission in immunocompromised patients. Failure to identify the ARF etiology is associated with increased mechanical ventilation and mortality rates. This was confirmed in the large Efraim 1 study published in 2017, where undetermined ARF etiology affected 609/1611 (38%) patients at day 3, 402 (25%) patients at day 7 and 199 (12.3%) patients overall, and was associated with a case fatality of 55% (vs. 40% in other patients). In lung biopsy/autopsy findings from these patients, invasive fungal infection, steroid-sensitive affections (organized pneumonia, non-infectious interstitial involvement, drug-related pulmonary toxicity…), and lung infiltration by the underlying disease (lymphoma, carcinomatous lymphangitis, systemic vasculitis, connective tissue diseases, etc.) were the leading etiologies. No study has evaluated survival benefits from empirical steroids and/or antifungals in immunocompromised patients with ARF from undetermined etiology. The main objective of this study is to reduce the 90-day mortality in immunocompromised patients with ARF from undetermined etiology at day-3. The intervention would evaluate the impact of steroids ± isavuconazole for 14 days or until ICU discharge.

NCT ID: NCT02983851 Not yet recruiting - Clinical trials for Acute Respiratory Failure

Initial Ventilation Strategy for Adult Immunocompromised Patients With Acute Respiratory Failure

Start date: December 2016
Phase: N/A
Study type: Interventional

VENIM is a multicenter, open-label, parallel-group randomized controlled trial of studying the initial ventilation strategy for adult immunocompromised patients with acute respiratory failure.